Thursday, March 14, 2024 9:24:42 PM
https://seekingalpha.com/news/4077812-patent-cliffs-could-fuel-increased-ma-in-oncology-this-year-cantor-says
Cantor sees strong year ahead for oncology M&A
Mar. 10, 2024 12:08 PM ETKura Oncology, Inc. (KURA) Stock, BCYC Stock, IMCR Stock, ALXO Stock, CGON StockJNJ, NVS, BMY, PFE, MRK, EXEL, GERN, FUSN, VSTM, KPTI, SNDX, MRUS, URGN, DCPH, MOR, ARVN, HARP, IDYA, SWTX, RVMD, ORIC, ZNTL, LEGN, RLAY, IMTX, PMVP, OLMA, DAWN, JANX, AMAM, ERAS, NUVLBy: Val Brickates Kennedy, SA News Editor9 Comments
Chessboard with chess pieces and wooden blocks with the word mergers and acquisitions
cagkansayin
Cantor Fitzgerald sees another strong year ahead for oncology M&A, with companies focused on antibody drug conjugates, radiopharmaceuticals and T-cell engagers expected to attract increased attention from major drugmakers looking to replenish pipelines.
Impending patent cliffs will be a big motivator for deals. According to Cantor, around $182B in revenue is at risk over the next four years due to patent expirations, with oncology products accounting for 42% of that number.
Several of the industry's biggest are set to lose patent protection by 2029, including Bristol Myers (BMY) Yervoy, Pomalyst and Opdivo; Johnson & Johnson’s (JNJ) Imbruvica; Merck’s (MRK) Keytruda; Pfizer’s (PFE) Ibrance; and Roche’s (OTCQX:RHHBY) Perjeta, according to Cantor.
Meanwhile, the global market for oncology drugs is expected to grow from $180B in 2022 to $323B in 2028, a rate that is “unparalleled to other therapeutics areas,” Cantor said. In comparison, the global biopharmaceutical market is expected to swell from $978B in 2022 to $1.39T in 2028.
Cantor estimates the industry should see between five and 17 acquisition deals this year, noting that three have already been announced to date: J&J/Ambrx (AMAM), Merck/Harpoon (HARP), and Novartis (NVS)/Morphosys (MOR).
The investment bank also pointed out that the pool of potential buyers is fairly deep as pretty much every major drugmaker has a presence in oncology, with Novo Nordisk (NVO) being a notable exception.
So what type of assets will Big Pharma be seeking out?
Cantor still sees a preference for de-risked assets but noted that proof-of-concept data for oncology drugs can often be achieved in Phase 1/2 testing. Drug candidates addressing larger markets, such as breast, lung or colorectal cancer, should be particularly attractive to potential buyers.
While small molecule candidates will probably account for around 50% of the deals, Cantor says complex biologics have been gaining in popularity. The bank sees assets such as antibody drug conjugates, radiopharmaceuticals and T-cell engagers as being particularly attractive acquisition targets this year, while synthetic lethality and TCR therapies could also see increased interest.
Cantor sees several companies in its coverage universe as potentially attracting suitors this year, including Kura (NASDAQ:KURA), Bicycle (NASDAQ:BCYC), Immunocore (NASDAQ:IMCR), ALX Oncology (NASDAQ:ALXO), Arvinas (ARVN), Immatics (IMTX), Verastem (VSTM), Oric (ORIC), and CG Oncology (NASDAQ:CGON).
Potential targets outside of its coverage include Day One (DAWN), Deciphera (DCPH), Erasca (ERAS), Exelixis (EXEL), Fusion (FUSN), Geron (GERN), Ideaya (IDYA), Karyopharm (KPTI), Janux (JANX), Legend Biotech (LEGN), Merus (MRUS), Nuvalent (NUVL), Olmea (OLMA), PMV (PMVP), Relay Therapeutics(RLAY), Revolution Medicines (RVMD), Syndax (SNDX), SpringWorks Therapeutics (SWTX), UroGen (URGN), and Zentalis (ZNTL).
Recent IMTX News
- Immatics Announces Full Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2024 05:52:26 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 01:58:09 PM
- Immatics Announces Pricing of $175 Million Public Offering • GlobeNewswire Inc. • 01/18/2024 01:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/17/2024 09:11:11 PM
- Immatics Announces Proposed Public Offering • GlobeNewswire Inc. • 01/17/2024 09:01:00 PM
- DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing • PR Newswire (US) • 01/16/2024 09:06:00 AM
- DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing • PR Newswire (US) • 01/16/2024 08:59:00 AM
- Levicept Appoints Eliot Forster as CEO • GlobeNewswire Inc. • 11/30/2023 09:00:00 AM
- Immatics Announces Third Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 11/14/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/08/2023 12:30:38 PM
- Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial • GlobeNewswire Inc. • 11/08/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/24/2023 11:10:46 AM
- Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy • GlobeNewswire Inc. • 10/24/2023 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/14/2023 04:15:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/13/2023 09:03:44 PM
- Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 10:33:54 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/25/2023 08:11:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/17/2023 11:05:17 AM
- Immatics Announces Second Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 08/17/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/10/2023 11:08:24 AM
- Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 08/10/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/24/2023 11:15:55 AM
- Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb • GlobeNewswire Inc. • 07/24/2023 11:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM